• New Covid test developed in US can identify all variants in hours, says report

    Health
    New Covid test developed in US can identify all variants in hours, says report




    mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#2F2F2F"> Digital Desk: US
    researchers have created a quick Covid-19 test kit that can identify every
    SARS-CoV-2 variation currently in existence within hours. The CoVarScan test
    finds the traces of eight hotspots on the Covid-19-causing SARS-CoV-2 virus.



    Calibri;mso-bidi-theme-font:minor-latin;color:#757575">CoVarScan was put to the
    test on samples taken from more than 4,000 patients by researchers at the
    University of Texas (UT) Southwestern Medical Center in the US.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">The study, which was
    just published in the journal Clinical Chemistry, demonstrates that the test
    can correctly distinguish between all current SARS-CoV-2 variations and is just
    as accurate as existing techniques for diagnosing Covid-19.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">According to Jeffrey
    SoRelle, an assistant professor at UT Southwestern and the study's principal
    author, "with this test, we can find out very rapidly what variants are in
    the community and if a new variant is forming."



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">When dealing with
    variants that react differently to medicines, it obviously has ramifications
    for specific patients, SoRelle added.

    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">Other Covid-19 assays
    are available, however they typically only detect tiny compounds on the surface
    of the virus or a piece of the SARS-CoV-2 genetic material, not the variation
    itself.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">Additionally, many
    scientists are concerned that these tests might miss emerging strains or that
    they are not reliable in detecting particular variants.                                                                                                                                                                                                                                                                                                                                 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">Whole genome sequencing,
    which is time-consuming and expensive and relies on advanced tools and analysis
    to spell out the whole RNA sequence contained in the viruses, is often required
    to identify which form of Covid-19 a patient carries.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">CoVarScan focuses on
    eight SARS-CoV-2 areas where viral variants frequently diverge.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">It analyses the length
    of repeating genomic areas that tend to grow and shrink as the virus matures
    and finds minor mutations where the sequence of RNA building blocks differs.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">The procedure copies and
    measures the RNA at these eight sites of interest using polymerase chain
    reaction (PCR), a technology used in most pathology labs.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">From April 2021 to
    February 2022, SoRelle's team gathered approximately 4,000 nasal swab samples
    from patients at UT Southwestern that tested positive for Covid-19. These
    samples were from both symptomatic and asymptomatic individuals.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">When making treatment
    decisions for some critically ill Covid-19 patients, the tests were validated
    using whole genome sequencing, the industry standard.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">CoVarScan showed 96%
    sensitivity and 99% specificity when compared to whole genome sequencing.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242">It recognised and
    distinguished the Delta, Mu, Lambda, and Omicron variations of Covid-19, as
    well as the BA.2 Omicron strain, which was formerly referred to as
    "stealth Omicron" since it was not detected by some tests meant to
    solely identify the Omicron strain.



    Calibri;mso-bidi-theme-font:minor-latin;color:#424242"> 



    According to a common criticism of this type of test, it must be
    adjusted frequently to account for new variants. However, CoVarScan has not
    required adjustment in more than a year and is still functioning quite well.



     "We could easily add as many as 20 or 30 additional hotspots
    to the test in the future, if we did need to change it," he continued.



    SoRelle has a pending patent application based on this study and
    intends to continue developing CoVarScan as a commercial test.